Acalabrutinib Real World Italian obSErvational Study -ARISE
← catalyst calendarNCT06205498 · readout in 254 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Yghea.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
151actual
Sites
41
Country
Italy
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-08 | actual | When the study began enrolling |
| Primary completion | 2027-04-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-04-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-01-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-23 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Lymphocytic Leukemia
Intervention
- Drug: acalabrutinib — also filed as Calquence
Primary outcome
what the primary-completion date above is the date OFtime to acalabrutinib discontinuation
measured through study completion, an average of 5 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed